Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Immunization Schedule"" wg kryterium: Temat


Tytuł:
The Advisory Committee on Immunization Practices' Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines - United States, February 2022.
Autorzy:
Wallace M
Moulia D
Blain AE
Ricketts EK
Minhaj FS
Link-Gelles R
Curran KG
Hadler SC
Asif A
Godfrey M
Hall E
Fiore A
Meyer S
Su JR
Weintraub E
Oster ME
Shimabukuro TT
Campos-Outcalt D
Morgan RL
Bell BP
Brooks O
Talbot HK
Lee GM
Daley MF
Oliver SE
Pokaż więcej
Źródło:
MMWR. Morbidity and mortality weekly report [MMWR Morb Mortal Wkly Rep] 2022 Mar 18; Vol. 71 (11), pp. 416-421. Date of Electronic Publication: 2022 Mar 18.
Typ publikacji:
Technical Report
MeSH Terms:
Advisory Committees*
Centers for Disease Control and Prevention, U.S.*
Health Planning Guidelines*
Immunization Schedule*
2019-nCoV Vaccine mRNA-1273/*administration & dosage
Adult ; Humans ; Middle Aged ; United States
Raport
Tytuł:
Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression.
Autorzy:
Feikin DR; Department of Immunisations, Vaccines, and Biologicals, WHO, Geneva, Switzerland. Electronic address: .
Higdon MM; International Vaccine Access Center, Department of International Health, John Hopkins Bloomberg School of Public Health, Baltimore, MA, USA.
Abu-Raddad LJ; Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Doha, Qatar.
Andrews N; UK Health Security Agency, London, UK.
Araos R; Instituto de Ciencias e Innovacion en Medicina, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Santiago, Chile; Advanced Centre for Chronic Diseases, Santiago, Chile.
Goldberg Y; Technion Israel Institute of Technology, Haife, Israel.
Groome MJ; National Institute for Communicable Diseases, Division of the National Health Laboratory Service, Johannesburg, South Africa; School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Huppert A; The Gertner Institute for Epidemiology and Health Policy Research, Sheba Medical Centre, Tel Aviv University, Tel Aviv, Israel.
O'Brien KL; Department of Immunisations, Vaccines, and Biologicals, WHO, Geneva, Switzerland.
Smith PG; MRC International Statistics and Epidemiology Group, London School of Hygiene & Tropical Medicine, London, UK.
Wilder-Smith A; Department of Immunisations, Vaccines, and Biologicals, WHO, Geneva, Switzerland.
Zeger S; Department of Epidemiology, John Hopkins Bloomberg School of Public Health, Baltimore, MA, USA.
Deloria Knoll M; International Vaccine Access Center, Department of International Health, John Hopkins Bloomberg School of Public Health, Baltimore, MA, USA.
Patel MK; Department of Immunisations, Vaccines, and Biologicals, WHO, Geneva, Switzerland.
Pokaż więcej
Źródło:
Lancet (London, England) [Lancet] 2022 Mar 05; Vol. 399 (10328), pp. 924-944. Date of Electronic Publication: 2022 Feb 23.
Typ publikacji:
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review
MeSH Terms:
Immunization Schedule*
Immunization, Secondary*
COVID-19/*prevention & control
COVID-19 Vaccines/*therapeutic use
Ad26COVS1/therapeutic use ; BNT162 Vaccine/therapeutic use ; Humans ; SARS-CoV-2/immunology ; SARS-CoV-2/isolation & purification ; Time Factors
SCR Organism:
SARS-CoV-2 variants
Czasopismo naukowe
Tytuł:
SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses.
Autorzy:
Chatterjee D; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
Tauzin A; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
Marchitto L; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
Gong SY; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 2B4, Canada.
Boutin M; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
Bourassa C; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
Beaudoin-Bussières G; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
Bo Y; Department of Biochemistry, Microbiology and Immunology, Center for Infection, Immunity, and Inflammation, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
Ding S; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
Laumaea A; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
Vézina D; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
Perreault J; Héma-Québec, Affaires Médicales et Innovation, Quebec, QC G1V 5C3, Canada.
Gokool L; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
Morrisseau C; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
Arlotto P; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
Fournier É; Laboratoire de Santé Publique du Québec, Institut Nationale de Santé Publique du Québec, Sainte-Anne-de-Bellevue, QC H9X 3R5, Canada.
Guilbault A; Laboratoire de Santé Publique du Québec, Institut Nationale de Santé Publique du Québec, Sainte-Anne-de-Bellevue, QC H9X 3R5, Canada.
Delisle B; Laboratoire de Santé Publique du Québec, Institut Nationale de Santé Publique du Québec, Sainte-Anne-de-Bellevue, QC H9X 3R5, Canada.
Levade I; Laboratoire de Santé Publique du Québec, Institut Nationale de Santé Publique du Québec, Sainte-Anne-de-Bellevue, QC H9X 3R5, Canada.
Goyette G; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
Gendron-Lepage G; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
Medjahed H; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
De Serres G; Institut National de Santé Publique du Québec, Quebec, QC H2P 1E2, Canada.
Tremblay C; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
Martel-Laferrière V; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
Kaufmann DE; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Médecine, Université de Montréal, Montreal, QC H3T 1J4, Canada.
Bazin R; Héma-Québec, Affaires Médicales et Innovation, Quebec, QC G1V 5C3, Canada.
Prévost J; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
Moreira S; Laboratoire de Santé Publique du Québec, Institut Nationale de Santé Publique du Québec, Sainte-Anne-de-Bellevue, QC H9X 3R5, Canada.
Richard J; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada. Electronic address: .
Côté M; Department of Biochemistry, Microbiology and Immunology, Center for Infection, Immunity, and Inflammation, University of Ottawa, Ottawa, ON K1H 8M5, Canada. Electronic address: .
Finzi A; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada; Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 2B4, Canada. Electronic address: .
Pokaż więcej
Źródło:
Cell reports [Cell Rep] 2022 Mar 01; Vol. 38 (9), pp. 110429. Date of Electronic Publication: 2022 Feb 08.
Typ publikacji:
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Immunization Schedule*
Antibodies, Neutralizing/*blood
BNT162 Vaccine/*administration & dosage
SARS-CoV-2/*immunology
Spike Glycoprotein, Coronavirus/*immunology
Adult ; Aged ; Antibodies, Neutralizing/analysis ; Antibodies, Neutralizing/immunology ; Antibodies, Viral/analysis ; Antibodies, Viral/blood ; Antibodies, Viral/immunology ; BNT162 Vaccine/immunology ; Cohort Studies ; Female ; HEK293 Cells ; Humans ; Immunization, Secondary/methods ; Male ; Middle Aged ; Quebec ; SARS-CoV-2/pathogenicity ; Time Factors ; Vaccination/methods ; Vaccine Potency ; Vaccines, Synthetic/administration & dosage ; Vaccines, Synthetic/immunology ; Young Adult ; mRNA Vaccines/administration & dosage ; mRNA Vaccines/immunology
SCR Organism:
SARS-CoV-2 variants
Czasopismo naukowe
Tytuł:
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2022.
Autorzy:
Murthy N
Wodi AP
Bernstein H
McNally V
Cineas S
Ault K
Pokaż więcej
Źródło:
MMWR. Morbidity and mortality weekly report [MMWR Morb Mortal Wkly Rep] 2022 Feb 18; Vol. 71 (7), pp. 229-233. Date of Electronic Publication: 2022 Feb 18.
Typ publikacji:
Journal Article
MeSH Terms:
Advisory Committees*
Health Planning Guidelines*
Immunization Schedule*
Adult ; Aged ; Centers for Disease Control and Prevention, U.S. ; Humans ; Middle Aged ; United States
Czasopismo naukowe
Tytuł:
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2022.
Autorzy:
Wodi AP
Murthy N
Bernstein H
McNally V
Cineas S
Ault K
Pokaż więcej
Źródło:
MMWR. Morbidity and mortality weekly report [MMWR Morb Mortal Wkly Rep] 2022 Feb 18; Vol. 71 (7), pp. 234-237. Date of Electronic Publication: 2022 Feb 18.
Typ publikacji:
Journal Article
MeSH Terms:
Advisory Committees*
Health Planning Guidelines*
Immunization Schedule*
Adolescent ; Centers for Disease Control and Prevention, U.S. ; Child ; Child, Preschool ; Humans ; Infant ; United States
Czasopismo naukowe
Tytuł:
Determinants of vaccine coverage and timeliness in a northern Pakistani village.
Autorzy:
Jamison AF; Division of International Epidemiology and Population Studies, Fogarty International Center, Bethesda, MD, United States of America.
McCormick BJJ; Science Fish Limited, Insch, Aberdeenshire, United Kingdom.
Hussain E; Administration Department, Karakoram International University, Gilgit, Gilgit-Baltistan, Pakistan.
Thomas ED; Division of International Epidemiology and Population Studies, Fogarty International Center, Bethesda, MD, United States of America.
Azam SI; Department of Community Health Sciences, Aga Khan University, Karachi, Sindh, Pakistan.
Hansen CL; Division of International Epidemiology and Population Studies, Fogarty International Center, Bethesda, MD, United States of America.
Rasmussen ZA; Division of International Epidemiology and Population Studies, Fogarty International Center, Bethesda, MD, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2022 Feb 17; Vol. 17 (2), pp. e0263712. Date of Electronic Publication: 2022 Feb 17 (Print Publication: 2022).
Typ publikacji:
Journal Article; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Immunization Schedule*
Socioeconomic Factors*
Immunization Programs/*standards
Measles/*prevention & control
Measles Vaccine/*administration & dosage
Vaccination/*statistics & numerical data
Vaccination Coverage/*statistics & numerical data
Adult ; Child, Preschool ; Female ; Humans ; Infant ; Infant, Newborn ; Longitudinal Studies ; Male ; Measles/epidemiology ; Measles/virology ; Morbillivirus/drug effects ; Morbillivirus/isolation & purification ; Pakistan/epidemiology
Czasopismo naukowe
Tytuł:
Pertussis vaccination in Chinese children with increasing reported pertussis cases.
Autorzy:
Zhang J; Department of Infectious Diseases, Shenzhen Children's Hospital, Shenzhen 518038, China.
Deng J; Department of Infectious Diseases, Shenzhen Children's Hospital, Shenzhen 518038, China.
Yang Y; Microbiology Laboratory, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China. Electronic address: .
Pokaż więcej
Źródło:
The Lancet. Infectious diseases [Lancet Infect Dis] 2022 Jan; Vol. 22 (1), pp. 21-22.
Typ publikacji:
Letter
MeSH Terms:
Immunization Schedule*
Pertussis Vaccine/*administration & dosage
Vaccination/*statistics & numerical data
Whooping Cough/*epidemiology
Whooping Cough/*prevention & control
Asians/statistics & numerical data ; Child ; Child, Preschool ; China/epidemiology ; Humans ; Infant ; Whooping Cough/mortality
Opinia redakcyjna
Tytuł:
Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma.
Autorzy:
Greenberg RS; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ruddy JA; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Boyarsky BJ; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Werbel WA; Department of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Garonzik-Wang JM; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Segev DL; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA. .; Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA. .
Imus PH; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2021 Dec 27; Vol. 21 (1), pp. 1354. Date of Electronic Publication: 2021 Dec 27.
Typ publikacji:
Journal Article
MeSH Terms:
Immunization Schedule*
2019-nCoV Vaccine mRNA-1273/*administration & dosage
Antibodies, Viral/*blood
BNT162 Vaccine/*administration & dosage
COVID-19/*prevention & control
Multiple Myeloma/*blood
2019-nCoV Vaccine mRNA-1273/adverse effects ; Aged ; BNT162 Vaccine/adverse effects ; COVID-19/epidemiology ; COVID-19 Vaccines/administration & dosage ; COVID-19 Vaccines/adverse effects ; Cohort Studies ; Female ; Humans ; Male ; Middle Aged ; Multiple Myeloma/epidemiology ; Prospective Studies ; Vaccination Hesitancy ; Vaccines, Synthetic/administration & dosage ; Vaccines, Synthetic/adverse effects ; mRNA Vaccines/administration & dosage ; mRNA Vaccines/adverse effects
Czasopismo naukowe
Tytuł:
A cross-sectional study evaluating tick-borne encephalitis vaccine uptake and timeliness among adults in Switzerland.
Autorzy:
Zens KD; Department of Public and Global Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.; Institute for Experimental Immunology, University of Zurich, Zurich, Switzerland.
Baroutsou V; Department of Public and Global Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.; Department of Clinical Research, Faculty of Medicine, University of Basel, Basel, Switzerland.
Sinniger P; Department of Public and Global Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
Lang P; Department of Public and Global Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2021 Dec 14; Vol. 16 (12), pp. e0247216. Date of Electronic Publication: 2021 Dec 14 (Print Publication: 2021).
Typ publikacji:
Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Immunization Schedule*
Motivation*
Vaccination*
Encephalitis, Tick-Borne/*prevention & control
Viral Vaccines/*administration & dosage
Adolescent ; Adult ; Aged ; Cross-Sectional Studies ; Encephalitis, Tick-Borne/epidemiology ; Female ; Humans ; Male ; Middle Aged
Czasopismo naukowe
Tytuł:
Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England.
Autorzy:
Amirthalingam G; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, United Kingdom. .
Bernal JL; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, United Kingdom.
Andrews NJ; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, United Kingdom.
Whitaker H; Statistics, Modelling and Economics Department, UK Health Security Agency, London, United Kingdom.
Gower C; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, United Kingdom.
Stowe J; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, United Kingdom.
Tessier E; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, United Kingdom.
Subbarao S; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, United Kingdom.
Ireland G; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, United Kingdom.
Baawuah F; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, United Kingdom.; Brondesbury Medical Centre, Kilburn, London, United Kingdom.
Linley E; Sero-Epidemiolgy Unit, UK Health Security Agency, Manchester, United Kingdom.
Warrener L; Virus Reference Department, UK Health Security Agency, London, United Kingdom.
O'Brien M; Brondesbury Medical Centre, Kilburn, London, United Kingdom.
Whillock C; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, United Kingdom.
Moss P; Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, United Kingdom.
Ladhani SN; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, United Kingdom.; Paediatric Infectious Diseases Research Group, St. George's University of London, London, United Kingdom.
Brown KE; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, United Kingdom.
Ramsay ME; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, United Kingdom.
Pokaż więcej
Źródło:
Nature communications [Nat Commun] 2021 Dec 10; Vol. 12 (1), pp. 7217. Date of Electronic Publication: 2021 Dec 10.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Immunization Schedule*
Vaccine Efficacy*
COVID-19/*prevention & control
COVID-19 Vaccines/*immunology
Aged ; Aged, 80 and over ; Antibodies, Viral/blood ; Antibody Formation ; BNT162 Vaccine ; COVID-19 Vaccines/administration & dosage ; ChAdOx1 nCoV-19 ; England ; Female ; Humans ; Male ; Middle Aged
Czasopismo naukowe
Tytuł:
Reaching zero-dose children in India: progress and challenges ahead.
Autorzy:
Murhekar MV; ICMR-National Institute of Epidemiology, Chennai, India. Electronic address: .
Kumar MS; ICMR-National Institute of Epidemiology, Chennai, India.
Pokaż więcej
Źródło:
The Lancet. Global health [Lancet Glob Health] 2021 Dec; Vol. 9 (12), pp. e1630-e1631.
Typ publikacji:
Journal Article
MeSH Terms:
Immunization Schedule*
Vaccination Coverage/*trends
Vaccines/*administration & dosage
Child ; Humans ; India ; Poverty/statistics & numerical data ; Public Health Practice/statistics & numerical data ; World Health Organization
Czasopismo naukowe
Tytuł:
Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer.
Autorzy:
McKenzie DR; The Francis Crick Institute, London, UK.
Muñoz-Ruiz M; The Francis Crick Institute, London, UK.
Monin L; The Francis Crick Institute, London, UK.
Alaguthurai T; Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London, UK; Breast Cancer Now Research Unit, King's College London, London, UK.
Lechmere T; Department of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, UK.
Abdul-Jawad S; Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London, UK.
Graham C; Department of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, UK.
Pollock E; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, UK.
Graham R; Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London, UK.
Sychowska K; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, UK.
Seow J; Department of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, UK.
Tremain C; Guy's and St. Thomas' NHS Foundation Trust, London, UK.
Gousis C; Guy's and St. Thomas' NHS Foundation Trust, London, UK.
Domingo-Vila C; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, UK.
Cooper J; Guy's and St. Thomas' NHS Foundation Trust, London, UK.
Vidler J; Department of Haematological Medicine, King's College Hospital, London, UK.
Owczarczyk K; Guy's and St. Thomas' NHS Foundation Trust, London, UK.
Swampillai A; Breast Cancer Now Research Unit, King's College London, London, UK; Guy's and St. Thomas' NHS Foundation Trust, London, UK.
Kristeleit H; Guy's and St. Thomas' NHS Foundation Trust, London, UK.
Malim MH; Department of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, UK.
Fields P; Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London, UK; Guy's and St. Thomas' NHS Foundation Trust, London, UK.
Patten PEM; Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London, UK; Department of Haematological Medicine, King's College Hospital, London, UK.
Papa S; Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London, UK; Guy's and St. Thomas' NHS Foundation Trust, London, UK.
North BV; Clinical Trials Unit, King's College London, UK.
Tree T; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, UK.
Doores KJ; Department of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, UK.
Hayday AC; The Francis Crick Institute, London, UK; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, UK.
Irshad S; Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London, UK; Breast Cancer Now Research Unit, King's College London, London, UK; Guy's and St. Thomas' NHS Foundation Trust, London, UK; Cancer Research UK (CRUK) Clinician Scientist, London, UK. Electronic address: .
Pokaż więcej
Źródło:
Cancer cell [Cancer Cell] 2021 Nov 08; Vol. 39 (11), pp. 1445-1447. Date of Electronic Publication: 2021 Oct 12.
Typ publikacji:
Letter
MeSH Terms:
Immunization Schedule*
Immunogenicity, Vaccine*
COVID-19/*prevention & control
COVID-19 Vaccines/*administration & dosage
Immunity, Cellular/*drug effects
Immunity, Humoral/*drug effects
Neoplasms/*immunology
SARS-CoV-2/*drug effects
Spike Glycoprotein, Coronavirus/*immunology
Antibodies, Viral/blood ; BNT162 Vaccine ; COVID-19/diagnosis ; COVID-19/immunology ; COVID-19/virology ; Case-Control Studies ; Cytokines/blood ; Host-Pathogen Interactions ; Humans ; Immunoglobulin G/blood ; SARS-CoV-2/immunology ; SARS-CoV-2/pathogenicity ; T-Lymphocytes/drug effects ; T-Lymphocytes/immunology ; T-Lymphocytes/virology ; Time Factors ; Treatment Outcome ; Vaccination
Opinia redakcyjna
Tytuł:
Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients.
Autorzy:
Harrington P; Department of Clinical Haematology, Guy's & St. Thomas' NHS Foundation Trust, London, UK; School of Cancer and Pharmaceutical Science, King's College London, London, UK.
Doores KJ; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
Saha C; Department of Clinical Haematology, Guy's & St. Thomas' NHS Foundation Trust, London, UK.
Saunders J; Department of Clinical Haematology, Guy's & St. Thomas' NHS Foundation Trust, London, UK.
Child F; Department of Clinical Haematology, Guy's & St. Thomas' NHS Foundation Trust, London, UK.
Dillon R; Department of Clinical Haematology, Guy's & St. Thomas' NHS Foundation Trust, London, UK; Department of Medicine & Molecular Genetics, King's College London, London, UK.
Saglam S; Department of Clinical Haematology, Guy's & St. Thomas' NHS Foundation Trust, London, UK.
Raj K; Department of Clinical Haematology, Guy's & St. Thomas' NHS Foundation Trust, London, UK.
McLornan D; Department of Clinical Haematology, Guy's & St. Thomas' NHS Foundation Trust, London, UK.
Avenoso D; Department of Haematological Medicine, King's College Hospital, London, UK.
Kordasti S; Department of Clinical Haematology, Guy's & St. Thomas' NHS Foundation Trust, London, UK; School of Cancer and Pharmaceutical Science, King's College London, London, UK.
O'Reilly A; Department of Clinical Haematology, Guy's & St. Thomas' NHS Foundation Trust, London, UK.
Espehana A; Department of Clinical Haematology, Guy's & St. Thomas' NHS Foundation Trust, London, UK.
Lechmere T; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
Khan H; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
Malim MH; Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.
Harrison C; Department of Clinical Haematology, Guy's & St. Thomas' NHS Foundation Trust, London, UK; School of Cancer and Pharmaceutical Science, King's College London, London, UK.
Mehra V; Department of Haematological Medicine, King's College Hospital, London, UK.
de Lavallade H; Department of Clinical Haematology, Guy's & St. Thomas' NHS Foundation Trust, London, UK; School of Cancer and Pharmaceutical Science, King's College London, London, UK. Electronic address: .
Pokaż więcej
Źródło:
Cancer cell [Cancer Cell] 2021 Nov 08; Vol. 39 (11), pp. 1448-1449. Date of Electronic Publication: 2021 Oct 12.
Typ publikacji:
Letter; Research Support, Non-U.S. Gov't
MeSH Terms:
Immunization Schedule*
Immunogenicity, Vaccine*
Stem Cell Transplantation*
COVID-19/*prevention & control
COVID-19 Vaccines/*administration & dosage
Immunity, Cellular/*drug effects
SARS-CoV-2/*drug effects
Spike Glycoprotein, Coronavirus/*immunology
T-Lymphocytes/*drug effects
Adult ; Aged ; Antibodies, Viral/blood ; BNT162 Vaccine ; COVID-19/immunology ; COVID-19/virology ; ChAdOx1 nCoV-19 ; Cytokines/blood ; Female ; Humans ; Immunoglobulin G/blood ; Lymphocyte Activation/drug effects ; Male ; Middle Aged ; SARS-CoV-2/immunology ; SARS-CoV-2/pathogenicity ; T-Lymphocytes/immunology ; T-Lymphocytes/virology ; Time Factors ; Transplantation, Homologous ; Treatment Outcome ; Vaccination
Raport
Tytuł:
Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
Autorzy:
Drolet M; Centre de recherche du CHU de Québec, Université Laval, Quebec City, QC, Canada.
Laprise JF; Centre de recherche du CHU de Québec, Université Laval, Quebec City, QC, Canada.
Martin D; Centre de recherche du CHU de Québec, Université Laval, Quebec City, QC, Canada.
Jit M; Centre for Mathematical Modelling of Infectious Disease, London School of Hygiene & Tropical Medicine, London, UK; Modelling and Economics Unit, Public Health England, London, UK; School of Public Health, University of Hong Kong, Hong Kong Special Administrative Region, China.
Bénard É; Centre de recherche du CHU de Québec, Université Laval, Quebec City, QC, Canada.
Gingras G; Centre de recherche du CHU de Québec, Université Laval, Quebec City, QC, Canada.
Boily MC; Centre de recherche du CHU de Québec, Université Laval, Quebec City, QC, Canada; Département de médecine sociale et preventive, Université Laval, Quebec City, QC, Canada; MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, Imperial College London, London, UK.
Alary M; Centre de recherche du CHU de Québec, Université Laval, Quebec City, QC, Canada; Département de médecine sociale et preventive, Université Laval, Quebec City, QC, Canada; Institut national de santé publique du Québec, Québec City, QC, Canada.
Baussano I; International Agency for Research on Cancer, Lyon, France.
Hutubessy R; Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
Brisson M; Centre de recherche du CHU de Québec, Université Laval, Quebec City, QC, Canada; Département de médecine sociale et preventive, Université Laval, Quebec City, QC, Canada; MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, Imperial College London, London, UK. Electronic address: .
Pokaż więcej
Źródło:
The Lancet. Infectious diseases [Lancet Infect Dis] 2021 Nov; Vol. 21 (11), pp. 1598-1610. Date of Electronic Publication: 2021 Jul 07.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Developing Countries*
Immunization Schedule*
Papillomavirus Infections/*prevention & control
Papillomavirus Vaccines/*administration & dosage
Papillomavirus Vaccines/*immunology
Uterine Cervical Neoplasms/*prevention & control
Adolescent ; Adult ; Child ; Cost-Benefit Analysis ; Female ; Humans ; Male ; Models, Biological ; Papillomavirus Vaccines/economics ; Quality-Adjusted Life Years ; Vaccination ; Young Adult
Czasopismo naukowe
Tytuł:
Influenza Vaccine Uptake in the Year After Concurrent vs Separate Influenza and Zoster Immunization.
Autorzy:
Rome BN; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.
Feldman WB; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Fischer MA; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.
Desai RJ; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.
Avorn J; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.
Pokaż więcej
Źródło:
JAMA network open [JAMA Netw Open] 2021 Nov 01; Vol. 4 (11), pp. e2135362. Date of Electronic Publication: 2021 Nov 01.
Typ publikacji:
Journal Article
MeSH Terms:
Immunization Schedule*
Herpes Zoster/*prevention & control
Herpes Zoster Vaccine/*administration & dosage
Influenza Vaccines/*administration & dosage
Influenza, Human/*prevention & control
Vaccination Coverage/*statistics & numerical data
Vaccination Coverage/*trends
Aged ; Aged, 80 and over ; Cohort Studies ; Female ; Humans ; Male ; Middle Aged ; Time Factors ; United States
Czasopismo naukowe
Tytuł:
What's the evidence for COVID-19 booster shots?
Autorzy:
Vogel L; CMAJ.
Duong D; CMAJ.
Pokaż więcej
Źródło:
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne [CMAJ] 2021 Sep 07; Vol. 193 (35), pp. E1400-E1401.
Typ publikacji:
Journal Article
MeSH Terms:
Immunization Schedule*
COVID-19/*prevention & control
COVID-19 Vaccines/*therapeutic use
Immunization, Secondary/*trends
COVID-19/epidemiology ; Canada ; Global Health ; Humans ; National Health Programs/organization & administration
Czasopismo naukowe
Tytuł:
Can the booster interval for the tick-borne encephalitis (TBE) vaccine 'FSME-IMMUN' be prolonged? - A systematic review.
Autorzy:
Steffen R; Epidemiology, Biostatistics and Prevention Institute, Department of Public and Global Health, Division of Infectious Diseases, World Health Organization Collaborating Centre for Travelers' Health, University of Zurich, Switzerland; Division of Epidemiology, Human Genetics & Environmental Sciences, University of Texas School of Public Health, Houston, TX, USA. Electronic address: .
Erber W; Pfizer Inc., Vienna, Austria.
Schmitt HJ; Pfizer Inc., Collegeville, USA.
Pokaż więcej
Źródło:
Ticks and tick-borne diseases [Ticks Tick Borne Dis] 2021 Sep; Vol. 12 (5), pp. 101779. Date of Electronic Publication: 2021 Jul 13.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Systematic Review
MeSH Terms:
Immunization Schedule*
Encephalitis Viruses, Tick-Borne/*immunology
Encephalitis, Tick-Borne/*prevention & control
Immunization, Secondary/*statistics & numerical data
Vaccination/*statistics & numerical data
Viral Vaccines/*immunology
Humans
Czasopismo naukowe
Tytuł:
Clinical Decision Support Reduces Unnecessary Tetanus Vaccinations in the Emergency Department.
Autorzy:
Dutta S; Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA; Massachusetts General Brigham Digital Health, Boston, MA; Harvard Medical School, Boston, MA. Electronic address: .
McEvoy DS; Massachusetts General Brigham Digital Health, Boston, MA.
Stump T; Massachusetts General Brigham Digital Health, Boston, MA.
McCabe J; Department of Emergency Medicine, Brigham and Women's Hospital, Boston, MA; Massachusetts General Brigham Digital Health, Boston, MA.
Mahendra-Rajah A; Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA.
McMurry R; Boston University School of Medicine, Boston, MA.
White BA; Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA; Harvard Medical School, Boston, MA.
Rubins D; Massachusetts General Brigham Digital Health, Boston, MA.
Pokaż więcej
Źródło:
Annals of emergency medicine [Ann Emerg Med] 2021 Sep; Vol. 78 (3), pp. 370-380. Date of Electronic Publication: 2021 May 08.
Typ publikacji:
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
MeSH Terms:
Immunization Schedule*
Decision Support Systems, Clinical/*standards
Tetanus Toxoid/*administration & dosage
Vaccination/*statistics & numerical data
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Emergency Service, Hospital/statistics & numerical data ; Female ; Humans ; Male ; Middle Aged ; Non-Randomized Controlled Trials as Topic ; Quality Improvement ; Retrospective Studies ; Tetanus Toxoid/adverse effects ; Tetanus Toxoid/immunology ; Unnecessary Procedures ; Young Adult
Czasopismo naukowe
Tytuł:
Parental Beliefs, Logistical Challenges, and Improvement Opportunities for Vaccination among Children Ages 19-35 Months Experiencing Homelessness.
Autorzy:
Gennaro E; Department of Pediatrics, Children's National Hospital, Washington, DC.
Caleb S; Department of Pediatrics, Children's National Hospital, Washington, DC.
Torres R; Center for Translational Research, Children's National Hospital, Washington, DC.
Alexander-Parrish R; Pfizer, Inc, Collegeville, PA.
Thoburn E; Pfizer, Inc, Collegeville, PA.
McLaughlin JM; Pfizer, Inc, Collegeville, PA.
Fu LY; Department of Pediatrics, Children's National Hospital, Washington, DC; Center for Translational Research, Children's National Hospital, Washington, DC.
Pokaż więcej
Źródło:
The Journal of pediatrics [J Pediatr] 2021 Sep; Vol. 236, pp. 246-252. Date of Electronic Publication: 2021 Apr 23.
Typ publikacji:
Journal Article
MeSH Terms:
Homeless Persons*
Immunization Schedule*
Parents*
Vaccination/*statistics & numerical data
Adult ; Child, Preschool ; Cross-Sectional Studies ; District of Columbia ; Female ; Health Services Accessibility ; Humans ; Infant ; Male ; Surveys and Questionnaires ; Young Adult
Czasopismo naukowe
Tytuł:
What a second booster dose of mRNA COVID-19 vaccines tells us.
Autorzy:
Loubet P; Department of Infectious and Tropical Diseases, CHU Nîmes, Nîmes 30029, France; VBMI, INSERM, Université de Montpellier, Nîmes, France. Electronic address: .
Launay O; French Clinical Research Infrastructure Network In Vaccinology, Paris, France; Assistance Publique Hôpitaux de Paris, CIC Cochin Pasteur, Hôpital Cochin, INSERM, Université Paris Cité, Paris, France.
Pokaż więcej
Źródło:
The Lancet. Infectious diseases [Lancet Infect Dis] 2022 Aug; Vol. 22 (8), pp. 1092-1093. Date of Electronic Publication: 2022 May 09.
Typ publikacji:
Journal Article; Comment
MeSH Terms:
COVID-19*/prevention & control
COVID-19 Vaccines*
Humans ; Immunization Schedule ; Immunization, Secondary ; RNA, Messenger ; Vaccines, Synthetic
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies

Prześlij opinię

Twoje opinie są dla nas bardzo ważne i mogą być niezwykle pomocne w pokazaniu nam, gdzie możemy dokonać ulepszeń. Bylibyśmy bardzo wdzięczni za poświęcenie kilku chwil na wypełnienie krótkiego formularza.

Formularz